Liza C. Villaruz

Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration

Alexander Drilon, Jeffrey W. Clark, Jared Weiss et al. · Nature Medicine · 2020 · 364 citations · Full text

Lung Cancers, Antitumor Activity, Medicine +9

IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain

Naoyuki Nogami, Fabrice Barlési, Mark A. Socinski et al. · Journal of Thoracic Oncology · 2021 · 283 citations · Full text

Neuro-oncology, Atezolizumab Plus Bevacizumab, Medicine +8

Efficacy and safety of crizotinib in patients with advanced <i>c-MET</i>-amplified non-small cell lung cancer (NSCLC).

D. Ross Camidge, Sai‐Hong Ignatius Ou, Geoffrey I. Shapiro et al. · Journal of Clinical Oncology · 2014 · 256 citations

Pathology, Pharmacotherapy, Pre-clinical Pharmacology +20

Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis

David Planchard, Benjamin Besse, Harry J.M. Groen et al. · Journal of Thoracic Oncology · 2021 · 253 citations · Full text

Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non–Small-Cell Lung Cancer Previously Treated With Immunotherapy—Lung-MAP S1800A

Karen L. Reckamp, Mary W. Redman, Konstantin H. Dragnev et al. · Journal of Clinical Oncology · 2022 · 228 citations · Full text